Pressure injuries assessing, treating and preventing infection

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.

Changes in climate constitute a reality that, according to recent projections, is going to worsen in the coming years.1 Increasing air pollution and climate change have an impact on respiratory health and mortality

In today's rapidly evolving healthcare environment, running a successful acute rehab program is more challenging than ever. At the same time, as providers shift to value-based care, post-acute treatment is playing an increasingly important role in ensuring positive outcomes. Providers looking to ensure high-quality rehabilitation care must ensure they're following industry best practices for success.

Differences in socioeconomic status, as assessed by educational attainment, income and occupational status, are associated with large disparities in health. Linked to a variety of health-related behaviours, socioeconomic status impacts prevalence of obesity, smoking, physical inactivity, high blood pressure, alcohol consumption and more.